Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells

作者：Momeny Majid; Sabourinejad Zahra; Zarrinrad Ghazaleh; Moghaddaskho Farima; Eyvani Haniyeh; Yousefi Hassan; Mirshahvaladi Shahab; Poursani Ensieh M; Barghi Farinaz; Poursheikhani Arash; Dardaei Leila; Bashash Davood; Ghazi Khansari Mahmoud; Tavangar Seyyed M; Dehpour Ahmad R; Yaghmaie Marjan; Alimoghaddam Kamran; Ghavamzadeh Ardeshir; Ghaffari Seyed H^*

来源：Scientific Reports, 2017, 7(1): 45954.

DOI：10.1038/srep45954

Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and succumb to chemoresistant disease. Overcoming drug resistance is the key to successful treatment of EOC. Members of vascular endothelial growth factor (VEGF) family are overexpressed in EOC and play key roles in its malignant progression though their contribution in development of the chemoresistant disease remains elusive. Here we show that expression of the VEGF family is higher in therapy-resistant EOC cells compared to sensitive ones. Overexpression of VEGFR2 correlated with resistance to cisplatin and combination with VEGFR2inhibitor apatinib synergistically increased cisplatin sensitivity. Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. Tivozanib decreased invasive potential of these cells, concomitant with reduction of intercellular adhesion molecule-1 (ICAM-1) and diminishing the enzymatic activity of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2). Moreover, tivozanib synergistically enhanced anti-tumour effects of EGFR-directed therapies including erlotinib. These findings suggest that the VEGF pathway has potential as a therapeutic target in therapy-resistant EOC and VEGFR blockade by tivozanib may yield stronger anti-tumour efficacy and circumvent resistance to EGFR-directed therapies.

• 出版日期2017-4-6